Toward Quality Care in ADHD: Defining the Goals of Treatment

Journal of Attention Disorders

Volumn 19, Issue 2, 2015, Pages 99-117

  Rostain, Anthony ^a   Jensen, Peter S ^b,c   Connor, Daniel F ^d   Miesle, Laura M ^e   Faraone, Stephen V ^f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b REsource for Advancing Children's Health   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^e The JB Ashtin Group Inc   (United States)

^f SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

ADHD; outcome measures; therapeutic goals; treatment terminology

Indexed keywords

EID: 84922134168     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054712473835     Document Type: Article

References (179)

1. Abikoff H. B. Vitiello B. Riddle M. A. Cunningham C. Greenhill L. L. Swanson J. M. Wigal T. (2007). Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 17, 581-592.
2. Abikoff H. B. McGough J. Vitiello B. McCracken J. Davies M. Walkup J. RUPP ADHD/Anxiety Study Group. (2005). Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 418-427.
3. Adler L. A. Goodman D. W. Kollins S. H. Weisler R. H. Krishnan S. Zhang Y. 303 Study Group. (2008). Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 69, 1364-1373.
4. Adler L. A. Liebowitz M. Kronenberger W. Qiao M. Rubin R. Hollandbeck M. Durell T. (2009). Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depression and Anxiety, 26, 212-221.
5. Adler L. A. Spencer T. J. Brown T. E. Holdnack J. Saylor K. Schuh K. Kelsey D. (2009). Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trial. Journal of Clinical Psychopharmacology, 29, 44-50.
6. Adler L. A. Spencer T. J. Levine L. R. Ramsey J. L. Tamura R. Kelsey D. Biederman J. (2008). Functional outcomes in the treatment of adults with ADHD. Journal of Attention Disorders, 11, 720-727.
7. Adler L. A. Sutton V. K. Moore R. J. Dietrich A. P. Reimherr F. W. Sangal R. B. Allen A. J. (2006). Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. Journal of Clinical Psychopharmacology, 26, 648-652.
8. Adler L. A. Zimmerman B. Starr H. L. Silber S. Palumbo J. Orman C. Spencer T. (2009). Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Journal of Clinical Psychopharmacology, 29, 239-247.
9. Ahmann P. A. Theye F. W. Berg R. Linquist A. J. Van Erem A. J. Campbell L. R. (2001). Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): Efficacy rate and side effects. Pediatrics, 107, E10.
10. American Academy of Child and Adolescent Psychiatry. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46(7), 894-921.
11. American Academy of Pediatrics. (2001). Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics, 108, 1033-1044.
12. American Psychiatric Association. (1993). Practice guideline for major depressive disorder in adults. American Journal of Psychiatry, 150(Suppl. 4), 1-26.
13. American Psychiatric Association. (2000a). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author
14. American Psychiatric Association. (2000b). Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry, 157(Suppl. 4), 1-45.
15. Andreasen N. C. Carpenter W. T. Jr Kane J. M. Lasser R. A. Marder S. R. Weinberger D. R. (2005). Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry, 162, 441-449.
16. Armenteros J. L. Lewis J. E. Davalos M. (2007). Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 558-565.
17. Arnold L. E. Lindsay R. L. Conners C. K. Wigal S. B. Levine A. J. Johnson D. E. Zeldis J. B. (2004). A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 14, 542-554.
18. Bangs M. E. Emslie G. J. Spencer T. J. Ramsey J. L. Carlson C. Bartky E. J. Sumner C. R. (2007). Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. Journal of Child and Adolescent Psychopharmacology, 17, 407-420.
19. Bangs M. E. Tauscher-Wisniewski S. Polzer J. Zhang S. Acharya N. Desaiah D. Allen A. J. (2008). Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. Journal of the American Academy of Child & Adolescent Psychiatry, 47, 209-218.
20. Barkley R. A. Fischer M. Edelbrock C. S. Smallish L. (1990). The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. Journal of the American Academy of Child & Adolescent Psychiatry, 29, 546-557.
21. Barkley R. A. Fischer M. Smallish L. Fletcher K. (2006). Young adult outcome of hyperactive children: Adaptive functioning in major life activities. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 192-202.
22. Barkley R. A. Guevremont D. C. Anastopoulos A. D. DuPaul G. J. Shelton T. L. (1993). Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: A 3- to 5-year follow-up survey. Pediatrics, 92, 212-218.
23. Barkley R. A. Murphy K. R. Fischer M. (2008). ADHD in adults: What the science says. New York, NY: Guilford.
24. Bastiaens L. (2008). Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic. Psychiatric Quarterly, 79, 133-137.
25. Biederman J. Faraone S. V. (2006). The effects of attention-deficit/hyperactivity disorder on employment and household income. MedGenMed: Medscape General Medicine, 8, 12.
26. Biederman J. Krishnan S. Zhang Y. McGough J. J. Findling R. L. (2007). Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clinical Therapeutics, 29, 450-463.
27. Biederman J. Melmed R. D. Patel A. McBurnett K. Konow J. Lyne A. SPD503 Study Group. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121, e73-84.
28. Biederman J. Mick E. Faraone S. V. (1998). Normalized functioning in youths with persistent attention-deficit/hyperactivity disorder. Journal of Pediatrics, 133, 544-551.
29. Biederman J. Mick E. Faraone S. V. (2000). Age-dependent decline of symptoms of attention deficit hyperactivity disorder: Impact of remission definition and symptom type. American Journal of Psychiatry, 157, 816-818.
30. Biederman J. Mick E. Surman C. Doyle R. Hammerness P. Harpold T. Spencer T. (2006). A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 59, 829-835.
31. Biederman J. Monuteaux M. C. Spencer T. Wilens T. E. Faraone S. V. (2009). Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics, 124, 71-78.
32. Biederman J. Monuteaux M. C. Spencer T. Wilens T. E. Macpherson H. A. Faraone S. V. (2008). Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: A naturalistic controlled 10-year follow-up study. American Journal of Psychiatry, 165, 597-603.
33. Biederman J. Spencer T. J. Newcorn J. H. Gao H. Milton D. R. Feldman P. D. Witte M. M. (2007). Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: A meta-analysis of controlled clinical trial data. Psychopharmacology, 190, 31-41.
34. Biederman J. Wilens T. Mick E. Spencer T. Faraone S. V. (1999). Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics, 104, e20.
35. Blader J. C. Schooler N. R. Jensen P. S. Pliszka S. R. Kafantaris V. (2009). Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. American Journal of Psychiatry, 166, 1392-1401.
36. Block S. L. Kelsey D. Coury D. Lewis D. Quintana H. Sutton V. Sumner C. (2009). Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: Comparison of morning and evening dosing. Clinical Pediatrics, 48, 723-733.
37. Brown R. T. Perwien A. Faries D. E. Kratochvil C. J. Vaughan B. S. (2006). Atomoxetine in the management of children with ADHD: Effects on quality of life and school functioning. Clinical Pediatrics, 45, 819-827.
38. Brown T. E. Landgraf J. M. (2010). Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: Evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgraduate Medicine, 122, 42-51.
39. Buitelaar J. K. Danckaerts M. Gillberg C. Zuddas A. Becker K. Bouvard M. Stomoxetine International Study Group. (2004). A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. European Journal of Child and Adolescent Psychiatry, 13, 249-257.
40. Buitelaar J. K. Michelson D. Danckaerts M. Gillberg C. Spencer T. J. Zuddas A. Biederman J. (2007). A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biological Psychiatry, 61, 694-699.
41. Buitelaar J. K. Wilens T. E. Zhang S. Ning Y. Feldman P. D. (2009). Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. Journal of Child Psychology and Psychiatry and Allied Disciplines, 50, 335-342.
42. Bush G. Spencer T. J. Holmes J. Shin L. M. Valera E. M. Seidman L. J. Biederman J. (2008). Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task. Archives of General Psychiatry, 65, 102-114.
43. Cannon M. Pelham W. H. Sallee F. R. Palumbo D. R. Bukstein O. Daviss W. B. (2009). Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 19, 511-517.
44. Carpentier P. J. de Jong C. A. Dijkstra B. A. Verbrugge C. A. Krabbe P. F. (2005). A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction, 100, 1868-1874.
45. Chacko A. Pelham W. E. Gnagy E. M. Greiner A. Vallano G. Bukstein O. Rancurello M. (2005). Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 249-257.
46. Cheng J. Y. Chen R. Y. Ko J. S. Ng E. M. (2007). Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology, 194, 197-209.
47. Cheon K. A. Cho D. Y. Koo M. S. Song D. H. Namkoong K. (2009). Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder. Biological Psychiatry, 65, 564-570.
48. Coghill D. R. Rhodes S. M. Matthews K. (2007). The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biological Psychiatry, 62, 954-962.
49. Conners C. K. Epstein J. N. March J. S. Angold A. Wells K. C. Klaric J. Wigal T. (2001). Multimodal treatment of ADHD in the MTA: An alternative outcome analysis. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 159-167.
50. Dell’Agnello G. Maschietto D. Bravaccio C. Calamoneri F. Masi G. Curatolo P. LYCY Study Group. (2009). Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. European Neuropsychopharmacology, 19, 822-834.
51. Depression Guideline Panel. (1993a). Depression in primary care: Volume 1, diagnosis and detection (Vol. Clinical Practice Guideline No. 5). Rockville, MD: US Department of Health and Human Services, Agency for Health Care Policy and Research.
52. Depression Guideline Panel. (1993b). Depression in primary care: Volume 2, treatment of major depression (Vol. Clinical Practice Guideline No. 5). Rockville, MD: US Department of Health and Human Services, Agency for Health Care Policy and Research.
53. DeVeaugh-Geiss J. Conners C. K. Sarkis E. H. Winner P. K. Ginsberg L. D. Hemphill J. M. Asgharnejad M. (2002). GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 914-920.
54. Dirksen S. J. D’Imperio J. M. Birdsall D. Hatch S. J. (2002). A postmarketing clinical experience study of Metadate CD. Current Medical Research and Opinion, 18, 371-380.
55. Durell T. M. Pumariega A. J. Rothe E. M. Tamayo J. M. Baron D. Williams D. (2009). Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder. Annals of Clinical Psychiatry, 21, 26-37.
56. Escobar R. Montoya A. Polavieja P. Cardo E. Artigas J. Hervas A. Fuentes J. (2009). Evaluation of patients’ and parents’ quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 19, 253-263.
57. Faraone S. V. Biederman J. Mick E. (2006). The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. Psychological Medicine, 36, 159-165.
58. Faraone S. V. Biederman J. Spencer T. J. Michelson D. Adler L. Reimherr F. Glatt S. J. (2005). Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: A drug-placebo response curve analysis. Behavioral and Brain Functions, 1, 16.
59. Faraone S. V. Biederman J. Spencer T. J. Wilens T. E. (2000). The drug-placebo response curve: A new method for assessing drug effects in clinical trials. Journal of Clinical Psychopharmacology, 20, 673-679.
60. Faraone S. V. Short E. J. Biederman J. Findling R. L. Roe C. Manos M. J. (2002). Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: A drug-placebo and drug-drug response curve analysis of a naturalistic study. International Journal of Neuropsychopharmacology, 5, 121-129.
61. Faraone S. V. Wilens T. E. Petty C. Antshel K. Spencer T. Biederman J. (2007). Substance use among ADHD adults: Implications of late onset and subthreshold diagnoses. American Journal of Addiction, 16(Suppl. 1), 24-32.
62. Findling R. L. Childress A. C. Krishnan S. McGough J. J. (2008). Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectrums, 13, 614-620.
63. Findling R. L. Quinn D. Hatch S. J. Cameron S. J. DeCory H. H. McDowell M. (2006). Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with attention deficit/hyperactivity disorder. European Child and Adolescent Psychiatry, 15, 450-459.
64. Findling R. L. Short E. J. Leskovec T. Townsend L. D. Demeter C. A. McNamara N. K. Stansbrey R. J. (2008). Aripiprazole in children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 18, 347-354.
65. Findling R. L. Wigal S. B. Bukstein O. G. Boellner S. W. Abikoff H. B. Turnbow J. M. Civil R. (2009). Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: A multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics, 31, 1844-1855.
66. Fischer M. Barkley R. A. Smallish L. Fletcher K. (2002). Young adult follow-up of hyperactive children: Self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. Journal of Abnormal Child Psychology, 30, 463-475.
67. Flapper B. C. Schoemaker M. M. (2008). Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD. Developmental Medicine & Child Neurology, 50, 294-299.
68. Frank E. Prien R. F. Jarrett R. B. Keller M. B. Kupfer D. J. Lavori P. W. Weissman M. M. (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry, 48, 851-855.
69. Ghuman J. K. Aman M. G. Lecavalier L. Riddle M. A. Gelenberg A. Wright R. Fort C. (2009). Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. Journal of Child and Adolescent Psychopharmacology, 19, 329-339.
70. Ghuman J. K. Ginsburg G. S. Subramaniam G. Ghuman H. S. Kau A. S. Riddle M. A. (2001). Psychostimulants in preschool children with attention-deficit/hyperactivity disorder: Clinical evidence from a developmental disorders institution. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 516-524.
71. Gibson A. P. Bettinger T. L. Patel N. C. Crismon M. L. (2006). Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Annals of Pharmacotherapy, 40, 1134-1142.
72. Goodman D. W. Ginsberg L. Weisler R. H. Cutler A. J. Hodgkins P. (2005). An interim analysis of the quality of life, effectiveness, safety, and tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrums, 10(12, Suppl. 20), 26-34.
73. Gothelf D. Gruber R. Presburger G. Dotan I. Brand-Gothelf A. Burg M. Weizman A. (2003). Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: An open-label study. Journal of Clinical Psychiatry, 64, 1163-1169.
74. Greenhill L. L. Findling R. L. Swanson J. M. (2002). A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics, 109, E39.
75. Greenhill L. L. Kollins S. Abikoff H. B. McCracken J. Riddle M. Swanson J. Cooper T. (2006). Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 1284-1293.
76. Greenhill L. L. Newcorn J. H. Gao H. Feldman P. D. (2007). Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 566-572.
77. Greenhill L. L. Wan G. J. Cooper K. M. (2004, May). Remission of ADHD with stimulant therapy (Abstract NR480). Paper presented at the American Psychiatric Association 2004 Annual Meeting, New York, NY.
78. Grizenko N. Bhat M. Schwartz G. Ter-Stepanian M. Joober R. (2006). Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: A randomized crossover trial. Journal of Psychiatry & Neuroscience, 31, 46-51.
79. Grizenko N. Kovacina B. Amor L. B. Schwartz G. Ter-Stepanian M. Joober R. (2006). Relationship between response to methylphenidate treatment in children with ADHD and psychopathology in their families. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 47-53.
80. Gualtieri C. T. Johnson L. G. (2008). Medications do not necessarily normalize cognition in ADHD patients. Journal of Attention Disorders, 11, 459-469.
81. Gurkan K. Bilgic A. Turkoglu S. Kilic B. G. Aysev A. Uslu R. (2010). Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. Journal of Psychopharmacology, 24, 1810-1818.
82. Halperin J. M. Trampush J. W. Miller C. J. Marks D. J. Newcorn J. H. (2008). Neuropsychological outcome in adolescents/young adults with childhood ADHD: Profiles of persisters, remitters and controls. Journal of Child Psychology and Psychiatry, 49, 958-966.
83. Handen B. L. Feldman H. M. Lurier A. Murray P. J. (1999). Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 38, 805-812.
84. Handen B. L. Johnson C. R. Lubetsky M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30, 245-255.
85. Hoare P. Remschmidt H. Medori R. Ettrich C. Rothenberger A. Santosh P. Trott G. E. (2005). 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. European Child and Adolescent Psychiatry, 14, 305-309.
86. Jensen P. S. (1999). Fact versus fancy concerning the multimodal treatment study for attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry, 44, 975-980.
87. Jensen P. S. Hinshaw S. P. Kraemer H. C. Lenora N. Newcorn J. H. Abikoff H. B. Vitiello B. (2001). ADHD comorbidity findings from the MTA study: Comparing comorbid subgroups. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 147-158.
88. Jensen P. S. Hinshaw S. P. Swanson J. M. Greenhill L. L. Conners C. K. Arnold L. E. Wigal T. (2001). Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): Implications and applications for primary care providers. Journal of Developmental & Behavioral Pediatrics, 22, 60-73.
89. Kaplan S. Heiligenstein J. West S. Busner J. Harder D. Dittmann R. Wernicke J. F. (2004). Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. Journal of Attention Disorders, 8, 45-52.
90. Karpenko V. Owens J. S. Evangelista N. M. Dodds C. (2009). Clinically significant symptom change in children with attention-deficit/hyperactivity disorder: Does it correspond with reliable improvement in functioning? Journal of Clinical Psychology, 65, 76-93.
91. Kelsey D. K. Sumner C. R. Casat C. D. Coury D. L. Quintana H. Saylor K. E. Allen A. J. (2004). Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics, 114, e1-8.
92. Kemner J. E. Starr H. L. Ciccone P. E. Hooper-Wood C. G. Crockett R. S. (2005). Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: A multicenter, randomized prospective study. Advances in Therapy, 22, 498-512.
93. Kemner J. E. Starr H. L. Ciccone P. E. Lynch J. (2004, May). OROS MPH provides greater ADHD symptom improvement than atomoxetine (Abstract NR451). Paper presented at the American Psychiatric Association 2004 Annual Meeting, New York, NY.
94. Kooij J. J. Burger H. Boonstra A. M. Van der Linden P. D. Kalma L. E. Buitelaar J. K. (2004). Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine, 34, 973-982.
95. Kooij J. S. Boonstra A. M. Vermeulen S. H. Heister A. G. Burger H. Buitelaar J. K. Franke B. (2008). Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B, 201-208.
96. Kowalik S. Minami H. Silva R. (2006). Dexmethylphenidate extended-release capsules for the treatment of attention deficit hyperactivity disorder. Expert Opinion on Pharmacotherapy, 7, 2547-2557.
97. Kratochvil C. J. Bohac D. Harrington M. Baker N. May D. Burke W. J. (2001). An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 11, 167-170.
98. Kratochvil C. J. Michelson D. Newcorn J. H. Weiss M. D. Busner J. Moore R. J. Allen A. J. (2007). High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 1128-1137.
99. Kratochvil C. J. Newcorn J. H. Arnold L. E. Duesenberg D. Emslie G. J. Quintana H. Biederman J. (2005). Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 915-924.
100. Krause J. la Fougere C. Krause K. H. Ackenheil M. Dresel S. H. (2005). Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. European Archives of Psychiatry and Clinical Neuroscience, 255, 428-431.
101. Kuperman S. Perry P. J. Gaffney G. R. Lund B. C. Bever-Stille K. A. Arndt S. Paulsen J. S. (2001). Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry, 13, 129-134.
102. Levin F. R. Evans S. M. Brooks D. J. Garawi F. (2007). Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug and Alcohol Dependence, 87, 20-29.
103. Levin F. R. Evans S. M. Brooks D. J. Kalbag A. S. Garawi F. Nunes E. V. (2006). Treatment of methadone-maintained patients with adult ADHD: Double-blind comparison of methylphenidate, bupropion and placebo. Drug and Alcohol Dependence, 81, 137-148.
104. Loo S. K. Teale P. D. Reite M. L. (1999). EEG correlates of methylphenidate response among children with ADHD: A preliminary report. Biological Psychiatry, 45, 1657-1660.
105. Mannuzza S. Klein R. G. Bessler A. Malloy P. Hynes M. E. (1997). Educational and occupational outcome of hyperactive boys grown up. Journal of the American Academy of Child & Adolescent Psychiatry, 36, 1222-1227.
106. Manos M. Frazier T. W. Landgraf J. M. Weiss M. Hodgkins P. (2009). HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Current Medical Research and Opinion, 25, 3001-3010.
107. Matza L. S. Johnston J. A. Faries D. E. Malley K. G. Brod M. (2007). Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). Quality of Life Research, 16, 1511-1520.
108. Matza L. S. Rentz A. M. Secnik K. Swensen A. R. Revicki D. A. Michelson D. Kratochvil C. J. (2004). The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. Journal of Developmental & Behavioral Pediatrics, 25, 166-174.
109. Matza L. S. Stoeckl M. N. Shorr J. M. Johnston J. A. (2006). Impact of atomoxetine on health-related quality of life and functional status in patients with ADHD. Expert Review of Pharmacoeconomics & Outcomes Research, 6, 379-390.
110. Maziade M. Rouleau N. Lee B. Rogers A. Davis L. Dickson R. (2009). Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: Results of a pilot study. Journal of Child and Adolescent Psychopharmacology, 19, 709-718.
111. McGough J. J. Biederman J. Wigal S. B. Lopez F. A. McCracken J. T. Spencer T. Tulloch S. J. (2005). Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 530-538.
112. Medori R. Ramos-Quiroga J. A. Casas M. Kooij J. J. Niemela A. Trott G. E. Buitelaar J. K. (2008). A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 63, 981-989.
113. Michelson D. Allen A. J. Busner J. Casat C. Dunn D. Kratochvil C. Harder D. (2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896-1901.
114. Michelson D. Buitelaar J. K. Danckaerts M. Gillberg C. Spencer T. J. Zuddas A. Biederman J. (2004). Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double-blind, placebo-controlled study. Journal of the American Academy of Child & Adolescent Psychiatry, 43, 896-904.
115. Michelson D. Faries D. Wernicke J. Kelsey D. Kendrick K. Sallee F. R. Atomoxetine ADHD Study Group. (2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics, 108, E83.
116. Mick E. Biederman J. Spencer T. Faraone S. V. Sklar P. (2006). Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 141B, 890-894.
117. Mick E. Faraone S. V. Spencer T. Zhang H. F. Biederman J. (2008). Assessing the validity of the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form in adults with ADHD. Journal of Attention Disorders, 11, 504-509.
118. Mitchell E. A. Aman M. G. Turbott S. H. Manku M. (1987). Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clinical Pediatrics, 26, 406-411.
119. Murphy K. Barkley R. A. (1996). Attention deficit hyperactivity disorder adults: Comorbidities and adaptive impairments. Comprehensive Psychiatry, 37, 393-401.
120. National Institute of Mental Health. (1999a). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA cooperative group. Multimodal treatment study of children with ADHD. Archives of General Psychiatry, 56, 1073-1086.
121. National Institute of Mental Health. (1999b). Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: The multimodal treatment study of children with attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1088-1096.
122. Newcorn J. H. Kratochvil C. J. Allen A. J. Casat C. D. Ruff D. D. Moore R. J. Atomoxetine/Methylphenidate Comparative Study Group. (2008). Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. American Journal of Psychiatry, 165, 721-730.
123. Newcorn J. H. Michelson D. Kratochvil C. J. Allen A. J. Ruff D. D. Moore R. J. (2006). Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder. Pediatrics, 118, e1701-1706.
124. Newcorn J. H. Spencer T. J. Biederman J. Milton D. R. Michelson D. (2005). Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 240-248.
125. Nikles C. J. Mitchell G. K. Del Mar C. B. Clavarino A. McNairn N. (2006). An n-of-1 trial service in clinical practice: Testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder. Pediatrics, 117, 2040-2046.
126. Pearson T. A. Blair S. N. Daniels S. R. Eckel R. H. Fair J. M. Fortmann S. P. Taubert K. A. (2002). AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation, 106, 388-391.
127. Perwien A. R. Kratochvil C. J. Faries D. E. Vaughan B. S. Spencer T. Brown R. T. (2006). Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: What are the long-term health-related quality-of-life outcomes? Journal of Child and Adolescent Psychopharmacology, 16, 713-724.
128. Pliszka S. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 894-921.
129. Prasad S. Harpin V. Poole L. Zeitlin H. Jamdar S. Puvanendran K. (2007). A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Current Medical Research and Opinion, 23, 379-394.
130. Prasad S. Steer C. (2008). Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder: Clinical approaches and review of current available evidence. Paediatric Drugs, 10, 39-47.
131. Ralston S. J. Lorenzo M. J. (2004). ADORE: Attention-deficit hyperactivity disorder observational research in Europe. European Child and Adolescent Psychiatry, 13(Suppl. 1), I36-I42.
132. Ramos-Quiroga J. A. Bosch R. Castells X. Valero S. Nogueira M. Gomez N. Casas M. (2008). Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: A chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs, 22, 603-611.
133. Ramos-Quiroga J. A. Casas M. (2011). Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder. CNS Drugs, 25, 17-36.
134. Ramoz N. Boni C. Downing A. M. Close S. L. Peters S. L. Prokop A. M. Gorwood P. (2009). A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology, 34, 2135-2142.
135. Reimherr F. W. Williams E. D. Strong R. E. Mestas R. Soni P. Marchant B. K. (2007). A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. Journal of Clinical Psychiatry, 68, 93-101.
136. Research Units on Pediatric Psychopharmacology Autism Network. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62, 1266-1274.
137. Rosler M. Fischer R. Ammer R. Ose C. Retz W. (2009). A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. European Archives of Psychiatry and Clinical Neuroscience, 259, 120-129.
138. Sallee F. R. Lyne A. Wigal T. McGough J. J. (2009). Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 19, 215-226.
139. Sangal R. B. Sangal J. M. (2004). Attention-deficit/hyperactivity disorder: Cognitive evoked potential (P300) topography predicts treatment response to methylphenidate. Clinical Neurophysiology, 115, 188-193.
140. Sangal R. B. Sangal J. M. (2005). Attention-deficit/hyperactivity disorder: Cognitive evoked potential (P300) amplitude predicts treatment response to atomoxetine. Clinical Neurophysiology, 116, 640-647.
141. Sangal R. B. Sangal J. M. (2006). Attention-deficit/hyperactivity disorder: Use of cognitive evoked potential (P300) to predict treatment response. Clinical Neurophysiology, 117, 1996-2006.
142. Satterfield J. H. Schell A. (1997). A prospective study of hyperactive boys with conduct problems and normal boys: Adolescent and adult criminality. Journal of the American Academy of Child & Adolescent Psychiatry, 36, 1726-1735.
143. Scahill L. Chappell P. B. Kim Y. S. Schultz R. T. Katsovich L. Shepherd E. Leckman J. F. (2001). A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry, 158, 1067-1074.
144. Silva R. Tilker H. A. Cecil J. T. Kowalik S. Khetani V. Faleck H. Patin J. (2004). Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 14, 555-563.
145. Sinzig J. Dopfner M. Lehmkuhl G. Uebel H. Schmeck K. Poustka F. Fischer R. (2007). Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 17, 421-432.
146. Spencer T. J. Biederman J. Heiligenstein J. Wilens T. Faries D. Prince J. Zervas S. (2001). An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 11, 251-265.
147. Spencer T. J. Biederman J. Wilens T. Doyle R. Surman C. Prince J. Faraone S. (2005). A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 57, 456-463.
148. Spencer T. J. Biederman J. Wilens T. Faraone S. Prince J. Gerard K. Bearman S. K. (2001). Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 58, 775-782.
149. Spencer T. J. Biederman J. Wilens T. Prince J. Hatch M. Jones J. Seidman L. (1998). Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. American Journal of Psychiatry, 155, 693-695.
150. Spencer T. J. Heiligenstein J. H. Biederman J. Faries D. E. Kratochvil C. J. Conners C. K. Potter W. Z. (2002). Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 63, 1140-1147.
151. Spencer T. J. Adler L. A. McGough J. J. Muniz R. Jiang H. Pestreich L. (2007). Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 61, 1380-1387.
152. Spencer T. J. Adler L. A. Weisler R. H. Youcha S. H. (2008). Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: A randomized, double-blind, multicenter, placebo-controlled study. Journal of Clinical Psychiatry, 69, 1437-1448.
153. Spencer T. J. Landgraf J. M. Adler L. A. Weisler R. H. Anderson C. S. Youcha S. H. (2008). Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: Results of a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 69, 1766-1775.
154. Steele M. (2005, May 21-26). Long term effectiveness and safety of Concerta in children with ADHD: A six month study (Abstract NR436). Paper presented at the American Psychiatric Association 2005 Annual Meeting, Atlanta, GA.
155. Steele M. Jensen P. S. Quinn D. M. (2006). Remission versus response as the goal of therapy in ADHD: A new standard for the field? Clinical Therapeutics, 28, 1892-1908.
156. Steele M. Weiss M. Swanson J. Wang J. Prinzo R. S. Binder C. E. (2006). A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Canadian Journal of Clinical Pharmacology, 13, e50-62.
157. Stein M. A. Sarampote C. S. Waldman I. D. Robb A. S. Conlon C. Pearl P. L. Newcorn J. H. (2003). A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics, 112, e404.
158. Sung V. Hiscock H. Sciberras E. Efron D. (2008). Sleep problems in children with attention-deficit/hyperactivity disorder: Prevalence and the effect on the child and family. Archives of Pediatrics and Adolescent Medicine, 162, 336-342.
159. Svanborg P. Thernlund G. Gustafsson P. A. Hagglof B. Poole L. Kadesjo B. (2009). Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. European Child and Adolescent Psychiatry, 18, 240-249.
160. Svanborg P. Thernlund G. Gustafsson P. A. Hagglof B. Schacht A. Kadesjo B. (2009). Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled study in Swedish children and adolescents. European Child and Adolescent Psychiatry, 18, 725-735.
161. Swanson J. M. Kraemer H. C. Hinshaw S. P. Arnold L. E. Conners C. K. Abikoff H. B. Wu M. (2001). Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 2, 168-179.
162. Szobot C. M. Ketzer C. Parente M. A. Biederman J. Rohde L. A. (2004). The acute effect of methylphenidate in Brazilian male children and adolescents with ADHD: A randomized clinical trial. Journal of Attention Disorders, 8, 37-43.
163. Taylor F. B. Russo J. (2000). Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. Journal of Child and Adolescent Psychopharmacology, 10, 311-320.
164. Trzepacz P. T. Williams D. W. Feldman P. D. Wrishko R. E. Witcher J. W. Buitelaar J. K. (2008). CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. European Neuropsychopharmacology, 18, 79-86.
165. U.S. Department of Health and Human Services: National Institutes of Health: National Heart, Lung, and Blood Institute. (2007). Expert panel report 3: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute.
166. Wehmeier P. M. Dittmann R. W. Schacht A. Minarzyk A. Lehmann M. Sevecke K. Lehmkuhl G. (2007). Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study. Journal of Child and Adolescent Psychopharmacology, 17, 813-830.
167. Weisler R. H. Biederman J. Spencer T. J. Wilens T. E. Faraone S. V. Chrisman A. K. Tulloch S. J. (2006). Mixed amphetamine salts extended-release in the treatment of adult ADHD: A randomized, controlled trial. CNS Spectrums, 11, 625-639.
168. Weiss G. Hechtman L. Milroy T. Perlman T. (1985). Psychiatric status of hyperactives as adults: A controlled prospective 15-year follow-up of 63 hyperactive children. Journal of the American Academy of Child Psychiatry & Adolescent Psychiatry, 24, 211-220.
169. Weiss M. Hechtman L. (2006). A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. Journal of Clinical Psychiatry, 67, 611-619.
170. Weiss M. Hechtman L. Turgay A. Jain U. Quinn D. Ahmed T. S. Darke A. C. (2007). Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 17, 675-688.
171. Weiss M. Tannock R. Kratochvil C. Dunn D. Velez-Borras J. Thomason C. Allen A. J. (2005). A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 647-655.
172. Wigal S. Swanson J. M. Feifel D. Sangal R. B. Elia J. Casat C. D. Conners C. K. (2004). A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 43, 1406-1414.
173. Wilens T. E. Biederman J. Mick E. (1998). Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. American Journal of Addiction, 7, 156-163.
174. Wilens T. E. Faraone S. V. Biederman J. Gunawardene S. (2003). Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 111, 179-185.
175. Wilens T. E. Kratochvil C. Newcorn J. H. Gao H. (2006). Do children and adolescents with ADHD respond differently to atomoxetine? Journal of the American Academy of Child & Adolescent Psychiatry, 45, 149-157.
176. Wilens T. E. McBurnett K. Bukstein O. McGough J. Greenhill L. Lerner M. Lynch J. M. (2006). Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Archives of Pediatrics and Adolescent Medicine, 160, 82-90.
177. Wilens T. E. Newcorn J. H. Kratochvil C. J. Gao H. Thomason C. K. Rogers A. K. Levine L. R. (2006). Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. Journal of Pediatrics, 149, 112-119.
178. Yoo H. K. Park S. Wang H. R. Lee J. S. Kim K. Paik K. W. Ko T. S. (2009). Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: An open-label study using an osmotic-controlled release oral delivery system. Epileptic Disorders, 11, 301-308.
179. Zeiner P. Bryhn G. Bjercke C. Truyen K. Strand G. (1999). Response to methylphenidate in boys with attention-deficit hyperactivity disorder. Acta Paediatrica, 88, 298-303.